Page 8 - Mike Beyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting | Region

LARKSPUR, Calif. (BUSINESS WIRE) Nov 3, 2023

United statesSan diegoMike beyerAron knickerbockerSam brown incSociety for immunotherapy of cancerAnnual meetingAulos bioscienceBiolojic designApple tree partnersSam brownBusiness wire

Passage Bio to Present at Guggenheim s 5th Annual Inflammation, Neurology & Immunology Conference - Passage Bio (NASDAQ:PASG)

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders,

United statesUniversity of pennsylvaniaMike beyerWilliam chouStuart hendersonUniversity of pennsylvania gene therapy programSam brown incHealthcare communicationsPassage bio incAnnual inflammationImmunology conferencePassage bioGene therapy programBio investorsBio media

Passage Bio to Present at Guggenheim s 5th Annual Inflammation, Neurology & Immunology Conference

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., president and chief executive officer, will participate in a fireside chat at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference on Monday, November 6, 2023 at 2:30 p.m. ET. A live webcast of the event will be available on

University of pennsylvaniaUnited statesStuart hendersonMike beyerWilliam chouPassage bio incSam brown incHealthcare communicationsUniversity of pennsylvania gene therapy programAnnual inflammationImmunology conferencePassage bioGene therapy programBio investorsBio mediaChief executive officer

MiNA Therapeutics Highlights Preclinical Research on RNA Activation (RNAa) Therapeutics Presented at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

MiNA Therapeutics Highlights Preclinical Research on RNA Activation (RNAa) Therapeutics Presented at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaMike beyerRobert habibOligonucleotide therapeutics societyTherapy development for theSam brown incMina therapeuticsTherapeutics limitedData highlightsChemically modified short activatingIncrease nuclease stabilityGene activationDisorder aniridiaBlood cancerPreclinical studies

MiNA Therapeutics Limited: MiNA Therapeutics Highlights Preclinical Research on RNA Activation (RNAa) Therapeutics Presented at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

MiNA Therapeutics Limited: MiNA Therapeutics Highlights Preclinical Research on RNA Activation (RNAa) Therapeutics Presented at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaMike beyerRobert habibIndiens wirtschaftIhre chancenOligonucleotide therapeutics societyMina therapeuticsTherapy development for theSam brown incData highlightsChemically modified short activatingIncrease nuclease stabilityGene activationDisorder aniridiaBlood cancerPreclinical studies